As of 2024-12-15, the Intrinsic Value of Karo Pharma AB (KARO.ST) is
9.55 SEK. This KARO.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 60.30 SEK, the upside of Karo Pharma AB is
-84.20%.
The range of the Intrinsic Value is (8.41) - 279.59 SEK
KARO.ST Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(8.41) - 279.59 |
9.55 |
-84.2% |
| DCF (Growth 10y) |
143.14 - 2,639.83 |
298.79 |
395.5% |
| DCF (EBITDA 5y) |
(14.57) - (10.15) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
41.80 - 66.27 |
51.21 |
-15.1% |
| Fair Value |
-17.36 - -17.36 |
-17.36 |
-128.79% |
| P/E |
(7.43) - 3.76 |
(2.66) |
-104.4% |
| EV/EBITDA |
(29.78) - (23.57) |
(26.89) |
-144.6% |
| EPV |
(4.50) - 4.84 |
0.17 |
-99.7% |
| DDM - Stable |
(10.26) - (103.80) |
(57.03) |
-194.6% |
| DDM - Multi |
24.19 - 192.78 |
43.20 |
-28.4% |
KARO.ST Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
16,477.28 |
| Beta |
0.15 |
| Outstanding shares (mil) |
273.25 |
| Enterprise Value (mil) |
24,854.98 |
| Market risk premium |
5.10% |
| Cost of Equity |
6.54% |
| Cost of Debt |
5.00% |
| WACC |
5.87% |